Update on the Treatment of Recurrent Ovarian Cancer
Open Access
- 1 January 2006
- journal article
- Published by SAGE Publications in Women's Health
- Vol. 2 (1) , 127-139
Abstract
Ovarian cancer is the leading cause of death for all gynecologic malignancies in developed countries, largely owing to the late stage of diagnosis. Despite response to initial surgery and chemotherapy, more than 65% of patients will have recurrent or persistent diseases. Approximately 50% of patients with recurrent ovarian cancer are asymptomatic. Recurrences are often diagnosed using a combination of tests, including cancer antigen 125, computed tomography, magnetic resonance imaging and positron emission tomography scan. The most significant prognostic factor among women with recurrent ovarian cancer is the length of time from initial diagnosis to recurrence. Treatment of recurrent ovarian cancer involves chemotherapy, with or without surgery. In selected patients, secondary cytoreductive surgery might significantly improve survival. Radiotherapy may have a role in the treatment of a small group of patients with localized symptomatic masses. New treatment modalities for women with recurrent ovarian cancer are needed, as none of the available treatments are curative.Keywords
This publication has 64 references indexed in Scilit:
- Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancerGynecologic Oncology, 2005
- A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinomaGynecologic Oncology, 2005
- Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel–platinumEuropean Journal of Surgical Oncology, 2005
- Critical evaluation of secondary cytoreduction in recurrent ovarian cancerGynecologic Oncology, 2004
- Tertiary cytoreduction in patients with recurrent ovarian carcinomaGynecologic Oncology, 2004
- Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?Cancer, 2004
- Salvage treatment with docetaxel for recurrent epithelial ovarian cancerInternational Journal of Clinical Oncology, 2003
- Positron Emission Tomography/Computed Tomography Imaging for the Detection of Recurrent Ovarian and Fallopian Tube Carcinoma: A Retrospective ReviewGynecologic Oncology, 2002
- Secondary Cytoreductive Surgery for Patients with Recurrent Epithelial Ovarian CarcinomaGynecologic Oncology, 2001
- Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-UpGynecologic Oncology, 2001